Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:23:28 EST Tue 13 Jan 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:FHTX - FOGHORN THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FHTX - Q0.15.67·8.001.26.38+1.2223.6387.22,1262,9715.42  6.50  5.406.7899  2.9448Jan 12Jan 0915 min RT 2¢

Recent Trades - Last 10 of 2971
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-09 22:20U:FHTXNews ReleaseFoghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
2025-11-25 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-05 07:00U:FHTXNews ReleaseFoghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
2025-11-03 07:30U:FHTXNews ReleaseFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences
2025-10-30 07:30U:FHTXNews ReleaseFoghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
2025-10-16 07:00U:FHTXNews ReleaseFoghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
2025-08-27 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences
2025-08-05 07:00U:FHTXNews ReleaseFoghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
2025-05-22 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Participate in Four Upcoming Investor Conferences
2025-05-14 07:00U:FHTXNews ReleaseFoghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
2025-05-05 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Participate in the Citizens Life Sciences Conference
2025-05-01 07:00U:FHTXNews ReleaseFoghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
2025-04-28 16:05U:FHTXNews ReleaseFoghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
2025-04-15 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
2025-03-25 16:35U:FHTXNews ReleaseFoghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
2025-03-06 16:05U:FHTXNews ReleaseFoghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
2025-02-25 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Participate in Two Upcoming Investor Conferences
2025-01-13 07:00U:FHTXNews ReleaseFoghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025